Investors should consider scooping up shares of this pharmaceutical giant trading at a discount, according to longtime value investor Bill Nygren. "
Merck is attractive on a standalone basis, and it's got really good portfolio characteristics," said the portfolio manager at Oakmark Funds, who bought shares in the third quarter.
MRK YTD mountain Shares this year Shares of Merck have underperformed the market this year, slumping more than 5%.
Beyond the big pharmaceutical name, Nygren is also finding value in some artificial intelligence implementers, in addition to mainstay megacap player Alphabet .
COF YTD mountain Shares this year Charter shares are up nearly 4% this year, while Capital One has rallied 43%.
Persons:
Bill Nygren, it's, Nygren, Rob Davis, Merck, bode
Organizations:
Merck, Oakmark, CNBC, Charter Communications, Capital
Locations:
financials, China